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Abstract
Background: Focused ultrasound combined with microbubble injection is capable of locally and transiently enhancing
the permeability of the blood-brain barrier (BBB). Magnetic resonance imaging (MRI) guidance enables to plan, monitor,
and characterize the BBB disruption. Being able to precisely and remotely control the permeabilization location is of great
interest to perform reproducible drug delivery protocols.
Methods: In this study, we developed an MR-guided motorized focused ultrasound (FUS) system allowing the transducer
displacement within preclinical MRI scanners, coupled with real-time transfer and reconstruction of MRI images, to help
ultrasound guidance. Capabilities of this new device to deliver large molecules to the brain on either single locations or
along arbitrary trajectories were characterized in vivo on healthy rats and mice using 1.5 MHz ultrasound sonications
combined with microbubble injection. The efficacy of BBB permeabilization was assessed by injecting a gadolinium-based
MR contrast agent that does not cross the intact BBB.
Results: The compact motorized FUS system developed in this work fits into the 9-cm inner diameter of the gradient
insert installed on our 7-T preclinical MRI scanners. MR images acquired after contrast agent injection confirmed that
this device can be used to enhance BBB permeability along remotely controlled spatial trajectories of the FUS beam in
both rats and mice. The two-axis motor stage enables reaching any region of interest in the rodent brain. The positioning
error when targeting the same anatomical location on different animals was estimated to be smaller than 0.5 mm. Finally,
this device was demonstrated to be useful for testing BBB opening at various acoustic pressures (0.2, 0.4, 0.7, and 0.9 MPa)
in the same animal and during one single ultrasound session.
Conclusions: Our system offers the unique possibility to move the transducer within a high magnetic field preclinical MRI
scanner, thus enabling the delivery of large molecules to virtually any rodent brain area in a non-invasive manner.
It results in time-saving and reproducibility and could be used to either deliver drugs over large parts of the brain
or test different acoustic conditions on the same animal during the same session, therefore reducing physiological
variability.
Keywords: Blood-brain barrier permeabilization, Focused ultrasound, High-field magnetic resonance imaging,
Drug delivery to rodent brains
* Correspondence: benoit.larrat@cea.fr
1UNIRS, Neurospin, I2BM, Direction des Sciences du Vivant, Commissariat à
l’Energie Atomique et aux Energies Alternatives, Bâtiment 145, 91191 Gif sur
Yvette, France
Full list of author information is available at the end of the article
© 2015 Magnin et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Magnin et al. Journal of Therapeutic Ultrasound  (2015) 3:22 
DOI 10.1186/s40349-015-0044-5
Background
Focused ultrasound (FUS) is an emerging field [1] which
has shown promising clinical results in a wide range of
indications, such a prostate cancer [2, 3], liver carcinomas
[4, 5], uterine fibroid [6, 7], or bone metastasis [8, 9]. In the
brain, FUS has shown its potential in thermal thalamotomy
for neuropathic pain [10] or essential tremor [11].
In the last decade, preclinical studies demonstrated that
burst sonications combined with intravenous injection of
microbubbles were able to disrupt the blood-brain barrier
(BBB) locally, transiently, and without damages, allowing
the delivery to brain tissues of large molecules which can-
not normally access the central nervous system (CNS) be-
cause of their size [12, 13]. Many feasibility studies have
investigated the capability of FUS-induced BBB disruption
to massively enhance the delivery of a wide variety of
therapeutic agents such as anticancer drugs [14–16], anti-
amyloid antibodies [17–19], siRNA, or nanoparticles [20].
Recently, repeated application of BBB permeabilization
protocols has also demonstrated its ability to reduce the
amyloid plaque load in mice model of Alzheimer’s disease,
without any use of therapeutic drug [21, 22]. A growing
number of studies have been exploring the optimal param-
eters for BBB disruption such as the influence of ultra-
sound parameters [23–26] and microbubble properties [27,
28], or the physiologic state of the animals (temperature,
anesthesia) [29] and the maximum gap size obtained in the
vascular walls and the closure dynamics [30]. Nevertheless,
the exact mechanism leading to BBB permeabilization is
still not fully understood. To be later transferred to
humans, or even disseminated as a tool for pharmaco-
logical proofs of concept, there is a need for further in-
vestigating BBB disruption in preclinical settings. The
variety of brain disease models available on rodents
makes them good candidates for these studies.
To carry out these studies, magnetic resonance im-
aging (MRI) monitoring of FUS experiment is widely
used. Indeed, the physical effects of ultrasound on the
brain can be directly visualized using dedicated se-
quences such as acoustic radiation force imaging (ARFI)
for ultrasound localization and in situ acoustic pressure
measurements [31, 32], or thermometry sequences to
measure temperature changes during thermal applica-
tions. In the meantime, standard sequences can be used
for anatomical targeting and radiological assessment of
desirable and undesirable tissue damages due to ultra-
sound application. Planning and monitoring the experi-
ment is of importance in order to avoid known risks
such as edema or hemorrhages due to excessive acoustic
pressure responsible for inertial cavitation of circulating
microbubbles. In the case of BBB permeabilization ex-
periments, the injection of MRI contrast agents, such
as gadolinium (Gd) chelates, also provides evidence of
the disruption, as well as accurate characterization of
the permeability [33]. In addition, it can be valuable to
have a real-time reconstruction and display of the MR
images to plan and monitor the experiment with a feed-
back on the FUS system.
To carry out MR-guided BBB permeabilization experi-
ments, a number of features are necessary. It requires a
system to hold the head to avoid movement during MR
acquisitions. A radiofrequency (RF) coil is also needed
for MR imaging. Finally, the possibility to position pre-
cisely the focal spot in the brain is essential. In this pur-
pose, a good solution is to use MR-compatible motors
allowing a displacement of the transducer [34] within
the magnet. It enables a fast and accurate repositioning
of the transducer, and moving the focal spot during soni-
cations also allows treating larger regions [22]. Unfortu-
nately, due to the limited space offered by preclinical
MRI scanners and the MR compatibility problems aris-
ing at high magnetic fields, these systems only operate
within 3-T clinical MRI scanners. Thus, one cannot
benefit from the advantages offered by dedicated preclin-
ical high magnetic field MRI scanners. Moreover, it can
be of great interest to have a system which can adapt to
different species to widen the experimental possibilities.
In this study, such a MR-compatible motorized system
operating in a 7-T preclinical MRI scanner was devel-
oped and validated. Efforts were put to develop inter-
changeable beds integrating the RF coil, ear bars, and a
bite bar, so that the setup could be used for different
species (rats and mice). In addition, real-time transfer
and reconstruction of MR images was implemented to
ensure a good monitoring of the experiment.
Finally, in vivo BBB opening along arbitrary trajectories
in the rodent brain under preclinical high magnetic field
(7 T) MR guidance is demonstrated. The capability of the
system to perform BBB opening experiments under sev-
eral different acoustic conditions in the same animal at
once is also demonstrated.
Methods
Ultrasound transducer
For the first experiments aimed at testing the motorization
in vivo, a single-element MR-compatible focused trans-
ducer (transducer A, diameter 25 mm, focal depth 20 mm,
Imasonic, France) resonating at 1.5 MHz was used and is
pictured in Fig. 3 [31]. In order to be able to target deeper
regions of the brain, a phased array annular transducer
with eight channels and a central frequency of 1.5 MHz
was also designed and purchased from Imasonic, France
(Fig. 1a). It consisted of a spherically curved phased array
of concentric rings made of piezoelectric composite em-
bedded in a plastic mount (transducer B, diameter 30 mm,
geometrical focal depth 20 mm). The use of several ele-
ments allowed electronic steering of the ultrasound beam
in depth. Both transducers were coupled to the rodent
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head with a water balloon filled with deionized and de-
gassed water and closed by a thin latex membrane. The ul-
trasounds were shot from top to down.
The balloon was connected to a water degassing sys-
tem. Degassed, deionized water circulated prior to the
experiments in order to eliminate air bubbles trapped in
the balloon. The circulation was stopped during MR ac-
quisitions to avoid artifacts induced by the water move-
ment. The hydrostatic pressure in the balloon could be
adjusted manually to inflate or deflate the balloon and
ensure proper coupling with the animal head.
In vitro acoustic calibration
The output pressure of the transducers and the full
width at half maximum (FWHM) of the focal spot were
measured in a degassed water tank, using a 200-μm cal-
ibrated hydrophone (HGL-0200, preamplifier AH-2020,
Onda Corporation, USA) mounted on a micrometric
3D positioning stage. The transducers were excited
with a 15-cycle pulse and 1-Hz repetition frequency.
The peak negative pressure at the focus was recorded
as a function of electrical power in order to provide a
calibration curve for each transducer. In addition, the
acoustic fields generated by the transducers were simu-
lated using Fields II software [35, 36] (see Fig. 1c). In
the water tank, the FWHM were measured to be re-
spectively 1.2*1.2*5.8 ± 0.1 mm for transducer A and
1.2*1.2*6.6 ± 0.1 mm for transducer B.
MR-compatible motorization
To be able to precisely position the ultrasound focal
spot in the rodent brain in 3D, the transducer holder
could be moved mechanically in xy plane by motors, in
addition to axial electronic steering along z axis for
transducer B (see Fig. 1a).
Piezoelectric step motors have been installed outside the
magnet and embedded in a Faraday cage to avoid emission
of RFs. A glass fiber stick enabled the transmission of the
motor displacement to the transducer (see Fig. 1a). This
experimental setup combined MR compatibility at high
magnetic field with a high degree of compactness.
For head/foot translation, the stick was linked via a ball
joint to a block coated with ceramic stripe on its edges.
Two identical motors (HR4, Nanomotion, Yoqneam, Israel)
were set on each side of the block (Fig. 1a, left). Ceramic
finger tips on the motors moved the block by pressing the
ceramic stripe, inducing a translation of the transducer
stage. The minimum step size was 0.005 millimeters
(mm), and the total range was 27 mm. The measure-
ment of the transducer position was achieved by an
embedded optical system, consisting of one optical
stripe attached under the block (MV 65-40 EP, Numerik
Jena, Germany), facing a diode optical encoder (LIK 21,
Numerik Jean, Germany). For absolute measurement,
two references were located on the stripe and were de-
tected during a motor initialization step at the begin-
ning of each experiment. Further displacements were
calculated with respect to these references.
Fig. 1 Overview of the setup. a On the left, the block with the motors stays outside the magnet, and the movement is transmitted to the transducer on
the right via a glass fiber stick. The cradle is holed to welcome an interchangeable bed which is plugged into it. b An interchangeable bed including a
plastic head holder with ear bars and bite bar and a dedicated ultrasound transparent coil. c Simulation of the acoustic pressure field generated by the
1.5-MHz monoelement transducer A. d A screen print of the software used to drive the motors and the ultrasound. e A scheme of the real-time data
transmission and reconstruction
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Left/right translation was achieved with a plastic disk
coated with ceramic and surrounding the glass fiber stick
(Fig. 1a, left). A rotation of the disk was induced by two
identical motors (HR2, Nanomotion, Yoqneam, Israel) set
on each side of the disk and vibrating in same phases. The
rotation was then converted to a translation with a rack
and pinion system positioned on the transducer stage
(Fig. 1a, right). The minimum step size was 0.0087 mm,
for a total displacement range of 15 mm. An optical sen-
sor (RIK 4, Numerik Jena, Germany) measured the dis-
placement and took advantage of one reference stripe (RS
29/16/900, Numerik Jena, Germany) in order to estimate
the absolute position.
The transducer stage consisted of a rectangular plastic
plate guided by rails along the cradle. On its top, a mobile
rack was guided in a perpendicular direction to convert
the rotation of the glass fiber stick into a translation. The
transducer holder was linked to its stage with a ball joint,
allowing freedom of movement in the three directions for
more efficient coupling to the rodent head.
Interchangeable beds
To facilitate the installation of the animals outside the
magnetic field, interchangeable beds were designed that
can be unplugged from the rest of the MRI cradle. Two
switchable beds were designed, one for mice and one for
rats and made of polyethylene terephthalate (PETP).
Each bed included a plastic holder made of ABS resin to
maintain the animal head during MRI acquisitions, an ac-
cess for gas anesthetics (inflow and outflow tubes), and an
MR RF coil (see Fig. 1b) and its corresponding tuning and
matching circuit. Ear bars were attached on each side of the
head holder with specially designed sockets. The sockets
could adapt to the head size of the animals. In front of the
head holder, a plastic mount held a bite bar or snaffle and
another stick which could be positioned above the animal
nose. Both could be adjusted in length and height, and the
holder could also be moved perpendicular to the cradle to
ensure a good adaptability.
Integrated radiofrequency MRI coils
For an extended access of the transducer to the animal
head while maximizing the SNR on the brain, several
coil geometries were investigated. The simplest and
more robust one is a single loop coil, whose diameter
was wide enough for the ultrasound beam to pass
through it and for extensive displacement of the trans-
ducer above the head.
The size of the RF resonator was adapted for each spe-
cies: the loop diameter was tighter for the mice in order to
maximize the filling factor. The resonators were made of
copper stripes mounted on the head holder itself, at a res-
onance frequency of 300 MHz corresponding to the Lar-
mor frequency of protons at 7 T. They were connected to
a balanced circuit fixed under the bed, which allowed
fine-tuning and matching of the resonance frequency via
variable capacitors. RF transmission from and to Bruker
amplifiers was made via a semi-rigid coaxial cable suitable
for high power (1000 W), which laid under the bed. Cap-
acitor adjustment from outside the magnet was carried
out by specially designed plastic screwdrivers.
Dedicated system control software
The dedicated Thermoguide® software (Image Guided
Therapy, Pessac, France; see Fig. 1d) was installed on the
ultrasound console. It allowed driving remotely the trans-
ducer and the motors by setting up trajectories and then
sending them for execution to the FUS electronics. A tra-
jectory is composed of segments defining straight dis-
placements. Ultrasound can be shot along these segments.
On the mechanical trajectory panel (Fig. 1d), one could
manually draw any arbitrary trajectory or define it more
accurately by entering the coordinates of the segments.
The motor speed can be tuned along each segment. The
electronic trajectory panel (Fig. 1d) allowed controlling
every ultrasound parameter (frequency, shot duration,
pulse repetition frequency, amplitude) and the steering in
depth if possible.
Once the trajectory was programmed, it was sent to the
generator via an Ethernet connection and stored in a
buffer before execution. The number of repetitions of
this trajectory and the pause between two repetitions
could be chosen, as well as different triggering options:
no trigger, a trigger before each trajectory, or a trigger
on every shot.
Real-time data transfer and monitoring
A pipeline filter implemented on the MRI console running
Paravision® software (Bruker, Germany) allowed real-time
reconstruction and visualization of acquired images dir-
ectly on the ultrasound console (Fig. 1e). During image ac-
quisition, the filter intercepted the raw K-space data and
sent them along with a header summarizing all acquisition
parameters to the ultrasound console through a TCP/IP
protocol. This real-time pipeline was successfully tested
for all standard Bruker MRI sequences. Specific data pro-
cessing could be applied in real time to the MR images,
such as a temperature estimation or thermal dose meas-
urement for thermometry experiments. In addition, a spe-
cific plug-in for the Thermoguide® software was developed
to select the target location for BBB permeabilization on
MR anatomical images. Then, the ultrasound focal spot
position was retrieved either automatically or manually
on phase images acquired with MR acoustic radiation
force imaging (MR-ARFI) sequence, and a motor feed-
back finally moved the transducer to its target position
(see Fig. 2).
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MRI acquisitions
All MRI acquisitions were performed in a 7-T preclinical
scanner (Pharmascan, Bruker, Ettlingen, Germany) equipped
with a 9-cm inner diameter 740-mT/m gradient insert.
In order to locate the ultrasound beam in vivo, an ARFI
sequence was set by adding two sinusoidal motion-
sensitizing gradients to a multi-slice multi-echo (MSME)
sequence, synchronized with ultrasound bursts so that the
acquired phase image is proportional to acoustic intensity
[31]. The following parameters were used: echo time (TE)/
repetition time (TR) = 28/1080 milliseconds (ms), spatial
resolution = 0.5 × 0.5 × 2 mm3, matrix size = 64 × 64 × 5,
number of averages = 2, duration of motion-encoding gra-
dients = 8 ms, duration of ultrasound bursts = 4 ms, and
total acquisition time = 2.5 min.
After BBB disruption protocol, a T1-weighted (T1w)
MSME sequence (TE/TR = 8.3/300 ms, spatial reso-
lution = 0.125 × 0.125 × 1 mm3, matrix size = 256 × 256 ×
10, 10 averages, acquisition time = 6.5 min) was acquired
to detect Gd chelates delivered to brain tissues due to
enhanced BBB permeability.
To control the safety of the BBB disruption protocol, es-
pecially to detect the potential presence of hemorrhages
or edema at the disruption site, a T2-weighted (T2w)
image was acquired at the end of the experiment, using a
Rapid Acquisition with Refocused Echoes (RARE) se-
quence, with the following parameters: TEeffective/TR = 30/
3800 ms, spatial resolution = 0.250 × 0.250 × 0.5 mm3,
matrix = 128 × 120 × 32, RARE factor = 8, 8 averages, ac-
quisition time = 7.5 min.
BBB permeabilization protocols
All animal experiments were performed in accordance
with national ethic laws (project authorization number:
12-058, site authorization number: B-91-272-01). Sprague
Dawley rats of 120 g (n = 10, Janvier, France) and C57Bl/6
(n = 1, Janvier, France) mice were used. Their heads were
chemically shaved to ensure proper coupling with the
transducer. They were anesthetized with isoflurane (1.5–
2 %) in a mixture of air and oxygen and then positioned
into the bed in prone position (Fig. 3). The ultrasound
transducer was coupled to the head via the water balloon
and echographic gel. A custom-made catheter (25 G),
filled with saline and 10 % heparine to avoid blood clot
formation, was inserted in the caudal vein, to inject micro-
bubbles and MRI contrast agent from outside the scanner
with minimal dead volume (tubing from Fisher Scientific
with an inner diameter of 0.5 mm). The motorized setup
was placed in the magnet bore hole with the animal head
at the isocenter.
An ARFI image was acquired to localize the ultrasound
focal spot (Fig. 2) and could be used to reposition the
ultrasound beam in the targeted region of interest. From
this starting point, the BBB permeabilization trajectory
was defined, including an ultrasound sequence and a mech-
anical displacement of the transducer if needed. Sonovue®
(Bracco, Italy) was administrated via a bolus injection
(1.5 × 108 bubbles/mL, 1.6 mL/kg, 2 s) in the catheter and
flushed with 100 μL of saline, immediately followed by the
sonication along the defined trajectory. Dotarem® (Guerbet,
France), a Gd chelate, was then injected (1.6 mL/kg, 2 s)
right after the sonications. T1w images were acquired to
visualize the contrast agent penetration at the expected
BBB permeabilization location. Different ultrasound proto-
cols were tested, using the 1.5-MHz single channel trans-
ducer. The whole protocol is summarized in Fig. 3.
The in situ acoustic pressure was estimated given the
calibration of the transducer in free water and a trans-
mission factor of 0.7 for the skull of 120-g rats (previ-
ously measured in a water tank).
Protocol #1: targeting accuracy in vivo
Protocol #1 was aimed at addressing the targeting accuracy
in vivo, by targeting the same location in the striatum on 3
different rats (Fig. 4). A focused BBB permeabilization was
then performed without moving the transducer with 3-ms
ultrasound shots followed by 97-ms pause, repeated during
1 min with a focal acoustic pressure of 0.6 MPa (transducer
Fig. 2 ARFI imaging and focal spot positioning procedure. Step 1: an anatomy image and an ARFI image are acquired and reconstructed in real
time. Step 2: the target is chosen on the anatomy image (a, blue arrow), while the current position of the focal spot is determined using the ARFI
phase image (b). Step 3: a feedback on the motors allows reaching the previously defined target location (b, red arrow). Step 4: the phase of an ARFI
image acquired after the transducer displacement allows verifying that the desired target location has been reached (c, blue arrow)
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A). The central position of the opening was then estimated
on T1w images acquired after the BBB permeabilization for
the three rats.
Protocol #2: BBB disruption along arbitrary trajectories
In protocol #2, several mechanical trajectories were
designed to demonstrate the feasibility of BBB
permeabilization along arbitrary trajectories. On rats
#2.1, #2.2, and #2.3, trajectories with “A,” “X,” and “E”
shapes were defined (Fig. 5). On rat #2.4, a trajectory
covering the whole left hemisphere was defined
(Fig. 6a). For all tested trajectories, continuous sonica-
tions were performed. They were repeated 60 times with a
100-ms pause between each execution and a moving
speed of 10 mm/s. Experiments were conducted with
transducer A. Finally, a trajectory covering the whole brain
was designed on rat #2.5 (Fig. 6d). The acoustic pressure
was kept constant to 0.6 MPa in situ along the trajectory
by adapting the transmitted power thanks to a map of the
rat skull transmission factor (data not shown). Transducer
B was used for this protocol.
The feasibility of hemispheric BBB permeabilization was
also investigated on a C57Bl6 mouse, using the same prep-
aration process and MRI sequences for rats. The sonication
pattern was 3-ms sonications every 100 ms, and the trans-
ducer was continuously moved along a line over a whole
hemisphere during 10 min (Fig. 6f). Dotarem® was then
injected to visualize the disruption.
Fig. 3 Overview of the BBB permeabilization experiment. The different steps are summed up in the first row. The rodents are shaved and installed
in the bed under anesthesia, and a catheter is set in the caudal vein. It is then inserted in the magnet where reference scans (second row, a and
b) and positioning procedure are performed using ARFI images and the motors. The BBB permeabilization procedure is performed followed by
MR contrast agent injection and post-permeabilization MR image acquisition (c). MB = microbubbles. The red arrow indicates the BBB
permeabilization visible by a contrast enhancement on the T1-weighted image (c)
Fig. 4 Targeting accuracy in vivo. T1-weighted images obtained after Gd injection on three different rats on which the same target in the right
striatum was chosen. The contrast enhancement is visible only where the BBB has been disrupted (red arrows). It appears that the position is
reproducible in these different rats
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Protocol #3: influence of acoustic pressure on BBB
permeabilization
Protocol #3 aimed at showing the possibility to test dif-
ferent acoustic conditions on the animal during the
same session. A square trajectory with 5-mm length was
defined on one rat (Fig. 7). Focal acoustic pressure var-
ied on each side of the square: 0.2, 0.4, 0.7, and 0.9 MPa
for rat #3.1. The sonications were continuous, repeated
60 times with a 100-ms pause between each execution,
and a moving speed of 7 mm/s. The total sonication
time was 3 min.
Results
Protocol #1: real-time monitoring and targeting accuracy
in vivo
Figure 2 shows a typical positioning procedure combining
our real-time image processing pipeline and our feedback
procedure applied to transducer position. During the first
step, an anatomical image (Fig. 2a) was sent to the US
console to precisely choose the desired target location of
BBB disruption. A first ARFI image was acquired, sent to
the console, and processed by the control software to
localize the current focal spot (Fig. 2b), which was either
automatically detected or could be manually pointed.
Once its coordinates have been determined, the motors
automatically moved the transducer to the previously de-
fined target position (Fig. 2c). Contrast enhancement on
T1w images acquired after Dotarem® injection (Fig. 4) con-
firm BBB permeabilization on three different rats where
the same target location in the striatum was defined. The
distance between the center of the focal spot and the end
of the olfactory bulb was measured in each image. The
maximum shift on BBB permeabilization location between
the three different rats was 0.5 mm. It has to be compared
to the resolution of the ARFI sequence used for positioning
(0.5 mm) and the size of the focal spot measured in water
tank (FWHM of 1.2 mm).
Protocol #2: BBB permeabilization along arbitrary
trajectories
The images obtained after BBB permeabilization and
Dotarem® injection are shown in Figs. 5 and 6. On T1w
images, Dotarem® reaching brain tissues where the BBB
has been disrupted are revealed by the contrast enhance-
ment due to T1 shortening of surrounded water mole-
cules. In Fig. 6, a contrast enhancement can be observed
30 min after Dotarem® injection in the whole targeted
hemisphere of both rats and mice, while no specific con-
trast variation is detected in the non-sonicated hemi-
sphere. One can notice that the contrast enhancement
in sonicated hemisphere is not perfectly homogenous
(Fig. 6b), in particular close to the left ventricle. The de-
signed trajectory (Fig. 6a) could explain this difference,
as the segments near the center of the trajectory (corre-
sponding to the position of the ventricle) are more
spaced. In the global BBB permeabilization experiment, a
homogenous contrast enhancement can be seen on the
whole brain, while no specific Gd penetration can be seen
in the cerebellum which has not been sonicated (Fig. 6d).
Figure 5 also confirms a specific contrast enhancement
along the expected BBB permeabilization location only.
On post-sonication T2w images, no radiological evidence
of brain damages was detected.
Protocol #3: influence of acoustic pressure on BBB
permeabilization
A contrast enhancement can be seen along the trajectory,
except on the side which experienced the lowest peak
negative pressure (0.2 MPa). This confirms a previous re-
sult showing a minimum acoustic pressure to be reached
for efficient BBB opening [28], estimated to be around
Fig. 5 BBB permeabilization along arbitrary trajectories. a, b, and c T1-weighted images obtained after Gd injection, showing contrast enhancement at
the permeabilization location. They were disrupted along trajectories representing, respectively, the letters “A,” “X,” and “E”
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Fig. 6 (See legend on next page.)
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0.4 MPa. We also noted on the T1w image that the square
exhibits wider permeabilization for increasing acoustic
pressure. This result could be explained by assuming that
the pressure field has a Gaussian profile, as it is the case in
free water. Thus, if the focal pressure is increased, the dis-
ruption threshold is reached over a wider portion of the
focal spot.
Discussion
The first results of this work support a successful integra-
tion of a head holder consisting of ear bars and a bite bar, a
dedicated RF coil, and an 8-channel ultrasound transducer
within the 90-mm gradient insert of a 7-T preclinical MRI
scanner. The interest of electronic steering in depth is not
only to change the depth of focus in the brain but also to
adapt the focal length depending on the inflation of the
coupling water balloon which can slightly vary from one
animal to the other. Furthermore, the use of external mo-
tors allows, from outside the magnet, to move the focal
point in the brain within a longitudinal (resp. perpendicu-
lar) range of 27 mm (resp. 15 mm), with an accuracy esti-
mated in vivo to be better than 0.5 mm. Finally, the design
of two different switchable beds offers the possibility to
perform BBB permeabilization experiments on either mice
or rats with the same setup. It has to be noted that the
whole system was designed to be highly modular, both on
the hardware side (several compact MR-compatible trans-
ducers available, several beds) and on the software side
(real-time MR data export and display, dedicated plug-ins
for automatic focal spot repositioning).
The system could be further improved by integrating
more sensitive and more homogeneous RF coils, by
further miniaturizing the transducers or by reducing
small mechanical vibrations during scans. It also needs
to be noted that the water flow in the balloon was
stopped and the transducer/motors were disconnected
as often as possible during imaging to avoid artifacts.
The coil tuning and matching as well as the shimming
in the brain did not change much with the transducer
position though.
In the first in vivo experiment, we demonstrate our
capability to transiently permeate the BBB at any arbi-
trary brain location previously chosen on MRI anatom-
ical images, with high reproducibility. As the location of
the disruption site can be modified thanks to the motors
without taking the animal out of the magnet, the system
is time-saving compared to iterative manual positioning.
Moreover, the dedicated Thermoguide® software, which
controls the ultrasound shots, allows planning 3D trajec-
tories of BBB disruption with both the mechanical dis-
placement and the electronic beam steering. Such a system
should be of great interest to study the dependency of BBB
disruption with the targeted brain region, for example, the
difference between white and gray matters or the influence
of vasculature. Our results demonstrate that this system
can achieve delivery of large amounts of MRI contrast
agents along virtually any arbitrarily chosen brain areas.
In the second in vivo proof of concept, this system was
used for hemispheric BBB disruption, while the other
hemisphere was kept as a control, or for BBB disruption
over the whole brain. Thus, it offers the unique perspective
to deliver therapeutic molecules to large regions of the
brain within a preclinical MRI. For example, this could be
helpful to perform therapeutic proof of concept studies on
pathologies affecting the whole CNS, such as Alzheimer’s
disease, for which repeated BBB permeabilization over
large regions of the brain have recently shown a great po-
tential [17, 22].
Despite the fact that many features are integrated in the
system, the complete BBB opening protocol remains quite
complex. First, the intravenous injection of microbubbles
in the tail vein still requires human skills and can some-
times be difficult (black mice for instance) or poorly re-
producible. The whole process of animal positioning and
preparation also remains time-consuming and limits the
(See figure on previous page.)
Fig. 6 Trajectory drawing and application to hemispheric and global permeabilization. a (resp. d and f) Trajectories which were designed in the
control software for hemispheric BBB disruption in rats (resp. global BBB permeabilization in rats and hemispheric BBB disruption in mice). c (resp. g)
Axial T1-weighted image obtained after Gd chelate injection, showing contrast enhancement only in the hemisphere which has been disrupted in rat
(resp. mice). b The corresponding T1-weighted image obtained in the same rat in horizontal orientation. e T1-weighted image obtained in horizontal
orientation for the rat with global BBB permeabilization
Fig. 7 Influence of acoustic pressure on BBB permeabilization.
T1-weighted image obtained after BBB permeabilization along a
square trajectory with different acoustic pressures on each side for
rat #3.1 and a scheme of the trajectory used
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number of animals that can undergo the protocol. This
is the price to pay to ensure the highest level of experi-
mental control. Thus, this system is more suitable for
therapeutic proof of concept in rodents and fundamen-
tal studies on the BBB opening mechanisms which are
still missing before global translation into clinics than
for large-group studies.
Our third in vivo application has shown that it is pos-
sible to test various acoustic conditions on the same
animal during one single session. This ensures a fair com-
parison of the effect of different ultrasound parameters
under the same physiological state. This is very important
since studies have shown that some physiological parame-
ters, such as vasoconstriction, play a major role in the effi-
ciency of BBB permeabilization [29]. Our results seem to
confirm the existence of a threshold on acoustic pressure
below which no penetration of contrast agents is ob-
served, meaning either that the BBB is not disrupted or
that the permeability is not enhanced enough to let a sig-
nificant amount of molecules penetrate into the brain tis-
sues. Although the existence of this threshold was already
observed for focal BBB permeabilization [24, 28], this is to
our knowledge the first time that it is exhibited for low-
pressure continuous sonications together with transducer
displacement. The dependence of this pressure threshold
with the local acoustic duty cycle during a moving beam
should be studied in future studies.
Finally, this system is also suitable for other applications
of MR-guided FUS than BBB disruption. Other transduc-
ers working at different frequencies can be mounted on
the system. For example, low frequencies can be better
suited for neurostimulation experiments [37–43], where it
will be of great interest to be able to choose a precise
stimulation location and to follow in real time the induced
neuronal activity with functional MRI [44]. On contrary,
high frequencies are more suited for thermal applications
(higher thermal deposition) [45], where it is also necessary
to precisely target the treatment site and to follow in real
time the delivered thermal dose using MR thermometry.
Conclusions
In this study, we developed a motorized MR-compatible
ultrasound system and demonstrated its capabilities to en-
hance the delivery of large molecules to the CNS either lo-
cally or over any large region of the brain. This enables to
test several acoustic conditions on one single animal dur-
ing one BBB disruption session. Reversibly, it can also be
used to measure spatial variability of BBB disruption in
different brain regions.
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